Drug Profile
Gliclazide modified release - Shiner Pharm
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Shiner Pharm Corp
- Class Antihyperglycaemics; Sulfonylureas
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 12 Feb 2016 Launched for Type-2 diabetes mellitus in Taiwan (PO) before February 2016